PHIA Koninklijke Philips N.V.

Philips expands peripheral vascular disease portfolio with the QuickClear mechanical thrombectomy system for blood clot removal

Philips expands peripheral vascular disease portfolio with the QuickClear mechanical thrombectomy system for blood clot removal



September 24, 2020

  • Powerfully simple thrombectomy solution provides physicians with an all-in-one, single-use aspiration catheter and pump system
  • Intuitive design eliminates the need for capital equipment, with easy setup supporting faster procedures times
  • Significantly smaller footprint provides the same or greater aspiration power as currently-available thrombectomy devices [1]      

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the innovative QuickClear mechanical thrombectomy system. The compact, single-use system provides an all-in-one aspiration pump and catheter for the removal of blood clots from the vessels of the peripheral arterial and venous systems [2]. The system’s innovative all-in-one design is simple to use while eliminating the need for capital equipment or costly accessories, with easy setup supporting faster procedures times. The Philips QuickClear Mechanical Thrombectomy System has received U.S. FDA 510(k) clearance and is available for sale in the U.S.

“This novel thrombectomy system is the latest addition to Philips’ market-leading portfolio for the diagnosis and treatment of peripheral vascular diseases,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “Its intuitive design simplifies the entire thrombectomy procedure workflow. By taking away the high initial capital expenditure costs associated with traditional mechanical thrombectomy systems, QuickClear can help bring cost-effective solutions to both the hospital and outpatient care settings.”

Simple, optimized performance

QuickClear simplifies the entire thrombectomy procedure workflow. The small footprint of the sterile device allows it to be placed easily and conveniently on the table next to the patient. With the touch of a button, the system is up and running at maximum aspiration power within seconds. The consistency of the aspiration power during the procedure provides physicians more control and supports faster procedure times. The system’s range of catheters includes a large 10F aspiration catheter, providing 59% more aspiration volume than 8F aspiration catheters [1].

“QuickClear is a simple and easy to use mechanical thrombectomy system,” said Bryan Fisher, MD, Chief of Vascular Surgery, Tristar Centennial Medical Center, Nashville, U.S. “The system is significantly smaller than other systems without compromising aspiration power. The convenience of the device really shines through with its single use and lack of capital equipment. I am excited about the potential of this device and the impact it will have on my practice and the patients I treat.”

Philips’ peripheral vascular portfolio already includes advanced interventional imaging systems for precision guidance; intravascular ultrasound (IVUS) catheters to assess the location of the disease and lesion morphology and guide and confirm the treatment; peripheral atherectomy devices to remove blockages; and peripheral therapy devices, such as Philips’ Stellarex drug-coated balloon, to treat lesions. Philips recently further extended this portfolio with the , maker of the Tack Endovascular System, a first-of-its-kind, minimal-metal, dissection repair device that provides precision treatment of peripheral arterial dissections following balloon angioplasty in above-the-knee (ATK) and below-the-knee (BTK) therapeutic interventions.

New Cardiovascular Horizons digital symposium

Today, September 24th at 19:00 ET Philips will host a symposium entitled ‘QuickClear Mechanical Thrombectomy System: A Powerfully Simple and Cost-Effective Solution’ as part of the digital education series. To register, visit .

The Philips QuickClear Mechanical Thrombectomy System is U.S. FDA 510(k) cleared and available for sale in the U.S., with future expansion of availability to other geographies planned.

[1] Testing performed in-house. Data on file.

[2] The Philips QuickClear mechanical thrombectomy system is indicated for the removal of soft, fresh emboli and thrombi from the vessels of the peripheral arterial and venous systems.

For further information, please contact:

Mark Groves

Philips Global Press Office

Tel:

Email:



Twitter:

Fabienne van der Feer

Philips Image Guided Therapy

Tel:

Email:



Twitter:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments

EN
24/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips announces 5,000th Zenition mobile C-arm system installation, a...

Philips announces 5,000th Zenition mobile C-arm system installation, advancing access to high-quality, efficient surgical and interventional care worldwide October 8, 2025 Global adoption milestone underscores innovation in mobile C-arm surgical and interventional imaging, with more than 15 million patients treated in 170+ countries every year Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the 5,000th installation of its Philips Zenition mobile surgery imaging system at Kolín Regional Hospital in the Czech Republic. Since its la...

 PRESS RELEASE

Philips unveils latest CT and MR innovations in radiation therapy, adv...

Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025 September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term valuePhilips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology Amsterdam, the Netherlands – At the American Society for Radiation Oncology () 2025 Annual Meeting, (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips joins Optum Healthcare’s network as a preferred provider in th...

Philips joins Optum Healthcare’s network as a preferred provider in the USA September 25, 2025 Philips’ ambulatory and diagnostic solutions and services are now available to 3.4 million Optum policyholders for enhanced outpatient cardiac monitoring Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has entered a national partnership in the USA with Optum Healthcare. The inclusion of Philips’ (MCOT) and Philips Extended Holter (ePatch) in the network is designed to enable earlier detection of cardiac conditions and timely cli...

 PRESS RELEASE

Philips intends to extend maturity of forward purchases of 4 million s...

Philips intends to extend maturity of forward purchases of 4 million shares for long-term incentive plans September 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA) announces today that it intends to extend the settlement of two forward contracts for 2 million long-term incentive plans shares each as part of the share repurchase program on June 14, 2023. The planned extension will postpone the original maturity dates in Q4 2025 by one year to a new maturity date in Q4 2026. Further details will be available via this . For further information, please contact:Michael FuchsPhil...

 PRESS RELEASE

Philips and Masimo announce innovation partnership to advance access t...

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies September 11, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and (NASDAQ: MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch